NICE u-turn backs combo for kidney cancer
In a turnaround from its earlier position, the National Institute for Health and Care Excellence is now endorsing NHS funding for Eisai’s Kisplyx plus everolimus for kidney cancer.
Read More
Tag: Afinitor
NICE backs Afinitor, Sutent for neuroendocrine tumours
Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs).
Read More
Novartis’ Afinitor gets NICE green light for kidney cancer
The National Institute for Health and Care Excellence has now published final guidelines backing routine NHS use of Novartis’ Afinitor in certain patients with advanced kidney cancer.
Read More
Six new medicines accepted for NHS use in Scotland
Cost regulators for NHS treatments in Scotland have backed six medicines offering new options to some patients with cancer, chronic migraine, high cholesterol and iron deficiency.
Read More
NICE reappraisals back Novartis’ Afinitor and Pfizer’s Xalkori
Cancer patients will likely get routine access to Novartis’ Afinitor and Pfizer’s Xalkori on the NHS after a positive recommendation was handed down from the National Institute for Health and Care Excellence.
Read More
NICE shoots down two CDF drugs
Patients with breast cancer and mantle cell lymphoma living in England and Wales have been dealt a blow after cost regulators rejected two drugs currently available through the Cancer Drugs Fund for routine NHS use.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
